GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Debt-to-EBITDA

VRCDF (Verici Dx) Debt-to-EBITDA : -0.24 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Verici Dx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.18 Mil. Verici Dx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.27 Mil. Verici Dx's annualized EBITDA for the quarter that ended in Jun. 2024 was $-1.89 Mil. Verici Dx's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Verici Dx's Debt-to-EBITDA or its related term are showing as below:

VRCDF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11   Med: -0.07   Max: -0.07
Current: -0.11

During the past 4 years, the highest Debt-to-EBITDA Ratio of Verici Dx was -0.07. The lowest was -0.11. And the median was -0.07.

VRCDF's Debt-to-EBITDA is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.635 vs VRCDF: -0.11

Verici Dx Debt-to-EBITDA Historical Data

The historical data trend for Verici Dx's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Debt-to-EBITDA Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
N/A - -0.07 -0.07

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial - -0.06 -0.07 -0.09 -0.24

Competitive Comparison of Verici Dx's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Verici Dx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Verici Dx's Debt-to-EBITDA falls into.


;
;

Verici Dx Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Verici Dx's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.163 + 0.377) / -7.876
=-0.07

Verici Dx's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.184 + 0.274) / -1.894
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Verici Dx  (OTCPK:VRCDF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Verici Dx Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Verici Dx's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines